2-Methyl-1,3-Thiazole-4-Carboxylic Acid

When the 4-Carboxyl Group Undergoes Mixed Anhydride Activation in Oxicam Synthesis

The synthesis of enolcarboxamide-type nonsteroidal anti-inflammatory drugs (NSAIDs) bearing a 2-methylthiazole pharmacophore—most notably the marketed 7.5 mg and 15 mg meloxicam dosage forms—relies on a convergent assembly route where 2-methyl-1,3-thiazole-4-carboxylic acid serves as the heterocyclic acetyl synthon. Commercial-scale batch records reviewed during API technology transfer document a recurrent processing hazard: the formation of the mixed anhydride intermediate with pivaloyl chloride in anhydrous N,N-dimethylacetamide at −15 °C to −5 °C is exothermic and, if cooling brine circulation fails, the localized temperature spike above +8 °C triggers premature decarboxylative elimination, dropping the yield by 18–25% and generating a non-spec 2-methylthiazole impurity that co-elutes with the API on a standard C18 column (USP Monograph meloxicam, Related Compounds Test). The stoichiometric insertion ratio employed in the subsequent amidification of 5-methylthiazol-2-amine is tightly maintained at 1.02–1.05 molar equivalents of the activated acid relative to the amine nucleophile; deviation beyond 1.10 equivalents leads to bis-acylated by-product formation detectable by LC-MS at m/z 434.2 that reduces the crude assay to below 98.0%. Compliance is governed by ICH Q7 Good Manufacturing Practice for active pharmaceutical ingredients, with specific residual solvent thresholds per ICH Q3C (pivalic acid limit ≤5000 ppm, Class 3) and elemental impurity control aligned with ICH Q3D. The downstream isolation pathway involves quenching onto ice‑water, liquid-liquid extraction into ethyl acetate, repeated brine washes, and crystallization from isopropanol/n-heptane to yield the penultimate intermediate with a polymorphic Form I habit confirmed by XRPD—a stage at which particle attrition in agitated thin-film dryers has been correlated with filtration resistance during final API isolation. Terminal finished products comprise meloxicam tablets (7.5 mg, 15 mg), intramuscular injection solutions, and veterinary oral suspensions compliant with USP/Ph. Eur. monographs and packaged in aluminium/aluminium blister lines running at 45 blisters/min with in-line NIR spectroscopic verification of dose uniformity.

In the final-stage amidification of 7-aminocephalosporanic acid (7-ACA) derivatives conducted in a multi-product antibiotic facility, 2-methyl-1,3-thiazole-4-carboxylic acid is deployed via its 2-thio-5-pyridyl active ester to install the C-7 acylamino sidechain that confers enhanced stability against Ambler class C β-lactamases. This approach was selected over the traditional acid chloride route to mitigate racemization risk at the C-7 α-carbon during large-batch processing in 3,000 L glass-lined vessels equipped with retreat-curve impellers. The coupling stoichiometry is calibrated at 1.15–1.25 molar equivalents of the active ester per mole of silylated 7-ACA, using N,O-bis(trimethylsilyl)acetamide as an in situ protecting agent; excess ester beyond 1.30 equivalents increases the organic load in the subsequent aqueous hydrolysis step, extending the phase split time in the Podbielniak centrifugal extractor beyond the design specification of ≤90 seconds and causing entrainment of dichloromethane into the penicillin‑G acylase enzymatic deprotection reactor—a failure mode that reduced enzyme activity by 15–20% across three consecutive production campaigns according to deviation reports filed with the site quality unit. The process solvent dichloromethane is controlled to ≤600 ppm in the dried cephalosporin intermediate per ICH Q3C Class 2 limits, and full monographs under USP General Chapter 〈621〉 Chromatography and Ph. Eur. 2.2.46 guide purity verification. Sterility assurance for the terminal sterile powder-fill lines follows FDA 21 CFR 211.113 with moist-heat sterilization at 121 °C for 15 minutes (F0 ≥ 15), while the limulus amebocyte lysate test end-point is set at ≤0.1 EU/mg. Finished dosage forms release as dry powder for reconstitution in vials of 500 mg and 1 g, targeted at community-acquired respiratory tract infections and uncomplicated skin-structure infections where the 2-methylthiazole-4-carbonyl substitution provides a pharmacokinetic half-life > 4 hours in humans.

Chlorination-to-Amide Processing Windows for 2-Methylthiazole-4-carboxanilide Fungicides

Agronomic field efficacy data generated across three growing seasons in southeast Asian rice paddies established that the phenylamide derivatives of 2-methyl-1,3-thiazole-4-carboxylic acid deliver curative activity against Rhizoctonia solani at spray rates of 150–250 g a.i./ha when formulated as an oil-in-water emulsion. The manufacturing campaign for such fungicidal building blocks is anchored by a thionyl chloride-mediated carboxyl-to-acyl chloride conversion executed in anhydrous toluene under a nitrogen sweep that exhausts through a caustic scrubber. Plant-scale reactors at the CL50 containment level are charged with 1.0 kg-mol of the acid and 1.08–1.12 kg-mol of thionyl chloride in the presence of 0.5 wt% N,N-dimethylformamide as a nucleophilic catalyst; off-gas HCl and SO₂ profiles are monitored via online FTIR to identify the endpoint when the absorbance at 2790 cm⁻¹ plateaus. A failure to maintain jacket temperature at 65–68 °C during the post‑reaction strip of excess thionyl chloride under reduced pressure (180–200 mbar) can cause localized hot-spots at the reboiler tube surface, leading to ring‑chlorination on the thiazole C-5 position—a side product identified by GC‑MS (retention index deviation +32 units on a 5%-phenyl-methylpolysiloxane column) that must remain below 0.15 area% in the technical acid chloride. The subsequent amidation with 2-chloro-4-trifluoromethoxyaniline is performed at a molar ratio of 1.02:1 (amine:acid chloride) in tetrahydrofuran with triethylamine as proton scavenger; when the addition time of the acid chloride solution exceeds 45 minutes in a 5 m³ batch, residual water accumulation from atmospheric moisture ingress shifts the triethylamine hydrochloride by-product morphology from needle-like to a pasty solid that fouls the in-line bag filter differential pressure to >0.8 bar, triggering safe-state interlock and a 3‑hour clearance ahead of crystallization. The final product is a non-systemic SDHI-class candidate controlled under FAO Specification 472/SC for suspension concentrates and subjected to the full CIPAC MT 184 (suspensibility) and MT 46.3 (wet sieve retention) test suite. Wettable powder and water-dispersible granule delivery platforms containing 25–50% active ingredient are then introduced through standard hydraulic boom sprayers calibrated to a droplet volume median diameter of 200–250 µm.

High-throughput screening of transition metal–catalysed C–C cross-couplings regularly identifies 2-methyl-1,3-thiazole-4-carboxylic acid as a cost-competitive bidentate O,N-ligand progenitor for copper(I) and manganese(II) centres that accelerate Ullmann-type diaryl ether formations and Chan–Lam aminations under air without the need for glove-box isolation. A process development report from a CDMO disclosed that a pre-formed complex generated simply by stirring the acid with CuI (10 mol% relative to the aryl iodide substrate) in N-methylpyrrolidone at 110 °C for 20 minutes before substrate injection achieved a turnover number of 82 (±5) across six consecutive re‑uses of the same mother liquor after cross-flow filtration through a 0.2 µm ceramic membrane—a filtration regime that preserved >90% of the soluble catalyst activity if the transmembrane pressure was held below 2.0 bar. This chemistry has been scaled to 50 L Hastelloy C-276 reactors for the synthesis of a bulk pharma intermediate where the thiazolecarboxylate ligand was added in 1.05 molar equivalents relative to the copper source, and the oxygen content in the reactor headspace was maintained at < 4 vol% via continuous nitrogen dilution to avoid ligand oxidative degradation that would otherwise produce a copper mirror on the reactor wall and a 12% drop in isolated yield. While there is no single regulatory monograph covering the ligand by itself, the resulting coupled intermediate is released under ICH Q11 quality-by-design principles, with acceptance criteria for copper residues ≤10 ppm by ICP-OES to meet the Option 1 permissible daily exposure per ICH Q3D. An ASTM International task group is currently investigating a round-robin protocol modeled on ASTM D8005-18 (accelerated copper strip corrosion) adapted for soluble ligand stability, although published data for this specific configuration is limited. The terminal fine-chemical output—a diaryl ether building block with a 95–99% assay—is subsequently used in the manufacture of kinase inhibitor scaffolds produced in batch sizes of 50–100 kg.

Can This Heterocyclic Acid Serve as a Fluorogenic Module in Point-of-Care IVD Kits?

The intrinsic fluorescence quantum yield of 2-methyl-1,3-thiazole-4-carboxylic acid (Φ = 0.18 in phosphate‑buffered saline at pH 7.4, λ_ex 345 nm / λ_em 430 nm) has been harnessed to design conjugation-ready haptens for lateral-flow immunoassay platforms that detect anti-streptolysin O antibodies in fingerstick whole blood. Activation of the carboxylic terminus proceeds via 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS) at a molar ratio of acid : EDC : NHS = 1 : 1.2 : 2.0 in 50 mM MES buffer (pH 6.0) for 30 minutes at ambient temperature. In a production run of 10,000 test strip intermediates, the average fluorophore-to-albumin conjugation stoichiometry was determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to be 12 ± 2; batches falling below a ratio of 9 exhibited a statistically significant loss of signal-to-noise ratio in the test line—below 2.5:1—and were rejected under the in-process AQL 0.65 sampling plan. The manufacturing environment is regulated under ISO 13485:2016 Clause 7.5.2 (Validation of Processes for Production) for the conjugation and lyophilization steps, with cleanroom classification ISO Class 8 (at-rest particle count ≤3,520,000 particles/m³ for ≥ 0.5 µm) monitored by real-time viable air monitoring. Conjugated bulk intermediate is lyophilized in a Genesis SQ freeze-dryer with a primary drying shelf temperature of −20 °C at 100 mTorr for 18 hours, and storage stability data through 36 months at +4 °C indicate that the fluorescence emission intensity degrades by ≤6% when the residual moisture content stays below 1.5% Karl Fischer. Downstream device assembly occurs in a continuous web-handling line where the dyed conjugate pad is laminated between a nitrocellulose membrane (capillary rise rate 135 ± 15 s/4 cm) and a cellulose sample pad, all die-cut to ±0.2 mm tolerance. The finished rapid test device is validated against a centralized turbidimetric assay (Roche cobas c 702) at a clinical correlation coefficient r ≥ 0.96 and is marked under CE IVDR 2017/746 Annex IX Chapter II, with the full immunoassay system incorporating a desiccant sachet and a test cassette housing moulded from crystal polystyrene conforming to USP Class VI.

Extruder Degassing and Torque Profiles When Grafting the Thiazole Moiety onto EPDM

Thermo-oxidative stabilisation of medium-voltage cable insulation formulated from ethylene-propylene-diene terpolymer (EPDM) has been achieved by reactive grafting of 2-methyl-1,3-thiazole-4-carboxylic acid onto the polymer backbone during continuous twin-screw compounding on a ZSK 58 Megacompounder (screw diameter 58 mm, L/D 44:1, co-rotating). The grafting reaction is initiated by 2.0 phr of 2,5-dimethyl-2,5-di(tert-butylperoxy)hexane at a barrel zone temperature profile of 190 °C (zone 4) → 230 °C (zone 8) with the thiazole acid powder fed downstream into the melt section at a 0.35 phr loading rate via a side-fed twin-screw gravimetric feeder equipped with a stirrer to prevent bridging at the hopper throat; the feeder loss-in-weight signal fluctuations above ±1.5% have been correlated with under-crosslinked gel spots in the final insulation, detected as protrusions by online laser diameter gauge (±0.5 µm resolution). Optimisation data compiled across 15 production trials demonstrated that increasing the thiazole acid content beyond 0.50 phr results in a sharp non-linear rise in motor specific energy from 0.22 kWh/kg to 0.31 kWh/kg accompanied by melt pressure oscillations at the strand die that exceed the ±3 bar control window, a rheological signature attributed to in-situ metal‑chelating clusters that raise the complex viscosity at low shear rate (0.1 rad/s) from 18,000 Pa·s to 27,000 Pa·s as measured by dynamic mechanical analysis in parallel-plate oscillatory mode per ISO 6721-10:2015. Oxidative induction time (OIT) testing performed at 210 °C under 50 mL/min oxygen flow in accordance with ASTM D3895-19 revealed the following matrix of results, which underpinned the selection of the 0.35 phr specification limit for full-scale production of 35 kV underground distribution cables:

Finished insulation compounds are assessed against IEC 60811-401:2012 (thermal endurance) and IEC 60502-2 for rated voltages 6 kV to 30 kV, with additional copper-contact compatibility verified by the absence of green staining after 7 days of ageing at 150 °C in accordance with EN 50363-5:2005. In contrast to conventional benzotriazole-based metal deactivators, the grafted thiazolecarboxylic acid moiety exhibits lower migration rates in hot mineral oil (ASTM IRM 902) at 100 °C due to covalent tethering; extraction tests quantified by HPLC-UV at 256 nm indicate a surface exudation level below 12 µg/dm² after 14 days, which falls well within the dielectric loss‑tangent drift limit of ≤8% specified in the utility procurement contract. Field‑aged cable samples recovered after 5 years of buried service in a subtropical coastal belt showed a retention of >85% original elongation at break when the initial thiazole‑grafted formulation was deployed, whereas an equivalent antioxidant package based on triazine‑phenol blends dropped to 62%, triggering the utility’s condition‑based replacement protocol.